A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: In vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4

Clinical Immunology and Immunopathology

Volumn 84, Issue 1, 1997, Pages 73-84

  Anderson, Darrell ^a   Chambers, Karen ^a   Hanna, Nabil ^a   Leonard, John ^a   Reff, Mitchell ^a   Newman, Roland ^a   Baldoni, John ^b   Dunleavy, Donna ^b   Reddy, Manjula ^b   Sweet, Raymond ^b   Truneh, Alemseged ^b  

^a BIOGEN   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHIMPANZEE; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT FIXATION; CONSENSUS SEQUENCE; CONTROLLED STUDY; GENETIC MARKER; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR UPREGULATION; SEQUENCE HOMOLOGY; T LYMPHOCYTE ACTIVATION;

EID: 18544404423     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1997.4363     Document Type: Article

References (41)

1. Herzog C. H., Walker C. H., Muller W. Anti-CD4 antibody treatment of patients with rheumatoid arthritis. I. Effect on clinical course and circulating T cells. J. Autoimmun. 2:1989;627.
2. Walker C., Herzog C., Rieber P., Riethmuller G., Muller W., Pichler W. J. Anti-CD4 antibody treatment of patients with rheumatoid arthritis. II. Effect ofin vivoin vitro. J. Autoimmun. 2:1989;643.
3. Horneff G., Burmester G. R., Emmrich F., Kalden J. R. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum. 34:1991;129.
4. Reiter C., Kakavand B., Rieber E. P., Schattenkirchner M., Riethmuller G., Kruger K. Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151: Clinical results and immunopharmacologic effects in an open study, including repeated administration. Arthritis Rheum. 34:1991;525.
5. Wendling D., Wijdenes J., Racadot E., Morel-Fourrier B. Therapeutic use of monoclonal anti-CD4 antibody in rheumatoid arthritis. J. Rheumatol. 18:1991;325.
6. Goldberg D., Morel P., Chatenoud L., Boitard C., Menkes C. J., Bertoye P. H., Revillard J. P., Bach J. F. Immunological effects of high dose administration of anti-CD4 antibody in rheumatoid arthritis patients. J. Autoimmun. 4:1991;617.
7. Choy E. H., Chikanza I. C., Kingsley G. H., Corrigall V., Panayi G. S. Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody. Scand. J. Immunol. 36:1992;291.
8. Moreland L. W., Bucy R. P., Tilden A., Pratt P. W., LoBuglio A., Khazaeli M., Everson M. P., Daddona P., Ghrayeb J., Kilgarriff C. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheum. 36:1993;307.
9. Van der Lubbe P. A., Reiter C., Breedveld F. C., Druger K., Schattenkirchner M., Sanders M. E., Riethmuller G. Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis. Arthritis Rheum. 36:1993;1375.
10. Choy E. H. S., Pizalis C., Bijl I. A., Kingsley G. H., Panayi G. S. The importance of dose and dosing regimen of anti-CD4 monoclonal antibody (mAb) in the treatment of rheumatoid arthritis (RA). Annu. Sci. Meeting Am. Coll. Rheum. 36:1993;A192.
11. Straus D. B., Weiss A. Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor. Cell. 70:1992;585.
12. Greenstein J. L., Burakoff S. J. The role of L3T4 (CD4) in T cell activation. Ann. Inst. Pasteur Immunol. 138:1987;134.
13. Eichmann K., Boyce N. W., Schmidt-Ullrich R., Jonsson J. I. Distinct functions of CD8 (CD4) are utilized at different sites of T lymphocyte-differentiation. Immunol. Rev. 109:1989;39.
14. Janeway C. A., Rojo J., Saisawa K., Dianani U., Portoles P., Title J., Haque S., Jones B. The co-receptor function of murine CD4. Immunol. Rev. 109:1989;77.
15. Alexander D. R., Cantrell D. A. Kinases and phosphatases in T-cell activation. Immunol. Today. 10:1989;200.
16. lck. Cell. 55:1988;301.
17. Engleman E. G., Benike C. J., Glickman E., Evans R. K. Antibodies to membrane structures that distinguish suppressor/cytotoxic and helper T lymphocyte subpopulations block the mixed leukocyte reaction in man. J. Exp. Med. 153:1981;193.
18. Shizuru J. A., Gregory A. K., Chao C. T., Fathman C. G. Islet allograft survival after a single course of treatment with antibody to L3T4. Science. 37:1987;278.
19. Morel P., Vincent C., Cordier G., Panaye G., Carosella E., Revillard J. P. Anti-CD4 monoclonal antibody administration in renal transplanted patients. Clin. Immunol. Immunopathol. 56:1990;311.
20. Waldor M. K., Sriram S., Hardy R., Herzenberg L., Lanier L., Lim M., Steinman L. Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker. Science. 227:1985;415.
21. +. Arthritis Rheum. 37:1994;834.
22. +. Clin. Exp. Immunol. 93:1993;301.
23. Newman R. A., Alberts J., Anderson D. R., Carner K., Heard C., Norton F., Raab R., Reff M. E., Shuey S., Hanna N. "Primatization" of recombinant antibodies for immunotherapy of human disease: a macaque/human chimeric antibody against human CD4. Biotechnology. 10:1992;1455.
24. Evans T. L., Miller R. A. Large-scale production of murine monoclonal antibodies using hollow fiber bioreactors. Bio-Techniques. 6:1988;762.
25. Doyle M. L., Louie G., Dal Monte P., Sokoloski T. Tight binding affinities determined from thermodynamic linkage to protons by titration colorimetry. Methods Enzymol. 259:1995;183.
26. Duncan A. R., Winter G. The binding site for C1q on IgG. Nature. 332:1988;738.
27. Reff M. E., Connor K., Chambers K. S., Chinn P. C., Leonard J. E., Raab R., Newman R. A., Hanna N., Anderson D. R. Depletion of B cellsin vivo. Blood. 83:1994;435.
28. Isaacs J. D., Watts R. A., Hazleman B. L., Hale G., Keogan M. T., Cobbold S. P., Waldmann H. Humanized monoclonal antibody therapy for rheumatoid arthritis. Lancet. 340:1992;748.
29. Poynton C. H., Mort D., Maughan T. S. Adverse reactions to Campath-1H monoclonal antibody (letter; comment). Lancet. 341:1993;1037.
30. Orthoclone OKT®3 Sterile Solution (muromonab-CD3), 1995, Physician's Desk Reference, 1762, Medical Economics Data Production Co. Montvale, NJ.
31. Toribio M. L., Martinez C., Marcos M. A., Marquez C., Cabrero E., de la Hera A. A role for T3+4-6-8-transitional thymocytes in the differentiation of mature and functional T cells from human prothymocytes. Proc. Natl. Acad. Sci. USA. 83:1986;6985.
32. Reinherz E. L., Kung P. C., Goldstein G., Schlossman S. F. A monoclonal antibody reactive with the human cytotoxic/suppressor T cell subset previously defined by a heteroantiserum termed TH2. J. Immunol. 124:1980;1301.
33. Rao P. E., Talle M. A., Kung P. C., Goldstein G. Five epitopes of a differentiation antigen on human inducer T cells distinguished by monoclonal antibodies. Cell. Immunol. 80:1983;310.
34. Maezawa N., Yano A. Two distinct cytotoxic T lymphocyte subpopulations in patients with Vogt-Koyanagi-Harada disease that recognize human melanoma cells. Microbiol. Immunol. 28:1984;219.
35. Evans R. L., Wall D. W., Platsoucas C. D., Siegal F. P., Fikrig S. M., Testa C. M., Good R. A. Thymus-dependent membrane antigens in man: inhibition of cell-mediated lympholysis by monoclonal antibodies to TH2 antigen. Proc. Natl. Acad. Sci. USA. 78:1981;544.
36. Dialynas D. P., Wilde D. B., Marrack P., Pierres A., Wall K. A., Havran W., Otten G., Loken M. R., Pierres M., Kappler J. Characterization of the murine antigenic determinant, designated L3T4a, recognized by monoclonal antibody GK1.5: Expression of L3T4a by functional T cell clones appears to correlate primarily with class II MHC antigen-reactivity (Review). Immunol. Rev. 74:1983;29.
37. de la Hera A., Toribio M. L., Marquez C., Martinez C. Interleukin 2 promotes growth and cytolytic activity in human T3+4-8- thymocytes. Proc. Natl. Acad. Sci. USA. 82:1985;6268.
38. Carteron N. L., Wofsy D., Seaman W. E. Induction of immune tolerance during administration of monoclonal antibody to L3T4 does not depend on depletion of L3T4+ cells. J. Immunol. 140:1988;173.
39. ++. Clin. Immunol. Immunopathol. 56:1990;373.
40. Hutchings P. R., O'Reilly L. O., Parish N. H., Waldmann H., Cooke A. The use of non-depleting anti-CD4 monoclonal antibody to re-establish tolerance to beta cells in NOD mice. Eur. J. Immunol. 22:1992;1913.
41. Qin S., Cobbold S. P., Pope H., Elliott J., Kioussis D., Davies J., Waldmann H. "Infectious" transplantation tolerance. Science. 259:1993;974.